Discussion of EMA Draft Guideline on Quality and Equivalence of Topical Products Based on Comparison of Approved Mometasone Furoate Drugs
Open Access
- 12 July 2024
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (8) , 2153-2169
Abstract
Introduction Today, the approval for a generic topical product includes the presentation of therapeutic equivalence to the originator based on clinical trials. To facilitate this procedure, in 2018 the European Medicines Agency (EMA) published a draft guideline on quality and equivalence of topical products, which includes request parameters regarding the quality of the newly developed generic product and test protocols for the implementation of equivalence tests regarding efficacy. Methods To date, no data are available on the quality and evidence of the proposed test conditions. In this study, we performed an in vitro penetration test (IVPT) following the terms of the EMA draft guideline on two authorized topical products for which therapeutic equivalence was already proven during the approval process. Results The complex biometric data processing revealed that in vitro equivalence could not be observed for all skin sections for either originator or generic product. Moreover, the necessity of the negative control proposed in the draft guideline is more than questionable. From the results presented, there were indications that a reduced number of skin donors would be sufficient to achieve statistically significant equivalence in the comparison of all applied formulations. Here, n = 7 donors was proposed instead of n \(\ge\) 12 as the EMA draft guideline demands, decreasing the degree of biodiversity simultaneously. Moreover, a higher number of independent replicates (n > 2) was proposed for proper statistics. Conclusion This bioequivalence study shows insufficient parameters, which should be discussed together with the EMA draft guideline.
Keywords
All Related Versions
This publication has 8 references indexed in Scilit:
- Evaluation of critical parameters for in vitro skin permeation and penetration studies using animal skin modelsEuropean Journal of Pharmaceutical Sciences, 2018
- Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal DrugPharmaceutical Research, 2017
- In vitro skin models as a tool in optimization of drug formulationEuropean Journal of Pharmaceutical Sciences, 2015
- Assessing Topical Bioavailability and Bioequivalence: A Comparison of the In vitro Permeation Test and the Vasoconstrictor AssayPharmaceutical Research, 2014
- Development of an In Vitro Release Test (IVRT) for a Vaginal Microbicide GelDissolution Technologies, 2010
- Use of Excised Human Skin to Assess the Bioequivalence of Topical ProductsSkin Pharmacology and Physiology, 2009
- Inter- and intra-individual variability in human skin barrier function: A large scale retrospective studyToxicology in Vitro, 2008
- Percutaneous Absorption. On the Relevance of in Vitro DataJournal of Investigative Dermatology, 1975